PH12012501774A1 - Pharmaceutical composition containing a tetrahydrofolic acid - Google Patents

Pharmaceutical composition containing a tetrahydrofolic acid

Info

Publication number
PH12012501774A1
PH12012501774A1 PH12012501774A PH12012501774A PH12012501774A1 PH 12012501774 A1 PH12012501774 A1 PH 12012501774A1 PH 12012501774 A PH12012501774 A PH 12012501774A PH 12012501774 A PH12012501774 A PH 12012501774A PH 12012501774 A1 PH12012501774 A1 PH 12012501774A1
Authority
PH
Philippines
Prior art keywords
tetrahydrofolic acid
pharmaceutical composition
composition containing
estrogen
progestogen
Prior art date
Application number
PH12012501774A
Other languages
English (en)
Other versions
PH12012501774B1 (en
Inventor
King Kristina
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36763829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12012501774(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of PH12012501774B1 publication Critical patent/PH12012501774B1/en
Publication of PH12012501774A1 publication Critical patent/PH12012501774A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
PH12012501774A 2006-07-06 2012-09-06 Pharmaceutical composition containing a tetrahydrofolic acid PH12012501774A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06014002 2006-07-06
PCT/EP2007/005764 WO2008003432A1 (en) 2006-07-06 2007-06-29 Pharmaceutical composition containing a tetrahydrofolic acid

Publications (2)

Publication Number Publication Date
PH12012501774B1 PH12012501774B1 (en) 2015-09-21
PH12012501774A1 true PH12012501774A1 (en) 2015-09-21

Family

ID=36763829

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12012501774A PH12012501774A1 (en) 2006-07-06 2012-09-06 Pharmaceutical composition containing a tetrahydrofolic acid

Country Status (31)

Country Link
EP (2) EP2040683B2 (enExample)
JP (1) JP2009542591A (enExample)
KR (2) KR20090033889A (enExample)
CN (3) CN101489563A (enExample)
AR (2) AR061958A1 (enExample)
AU (1) AU2007271449B2 (enExample)
BR (1) BRPI0713565B8 (enExample)
CA (2) CA2856344C (enExample)
CL (1) CL2007001962A1 (enExample)
CO (1) CO6150125A2 (enExample)
CR (1) CR10549A (enExample)
CU (1) CU20090004A7 (enExample)
EC (1) ECSP099030A (enExample)
ES (1) ES2626838T5 (enExample)
GT (1) GT200900001A (enExample)
IL (3) IL196027A0 (enExample)
MA (1) MA30598B1 (enExample)
MX (1) MX2009000079A (enExample)
MY (1) MY169516A (enExample)
NO (1) NO347567B1 (enExample)
NZ (1) NZ573766A (enExample)
PE (3) PE20080273A1 (enExample)
PH (1) PH12012501774A1 (enExample)
RU (2) RU2479306C2 (enExample)
SG (1) SG188869A1 (enExample)
TN (1) TNSN08543A1 (enExample)
TW (2) TWI508730B (enExample)
UA (2) UA105078C2 (enExample)
UY (1) UY30462A1 (enExample)
WO (1) WO2008003432A1 (enExample)
ZA (4) ZA200900868B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
UY32836A (es) * 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
MX356702B (es) 2010-04-15 2018-06-11 Bayer Ip Gmbh Formas de dosificación sólidas orales con dosis muy bajas para la hrt.
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
CN102516247A (zh) * 2010-12-15 2012-06-27 连云港金康医药科技有限公司 A型l-5-甲基四氢叶酸钙盐多晶型及其制备方法
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
EP2781214A1 (en) * 2013-03-22 2014-09-24 Chemo Research, S.L. Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)
EP2878600B1 (en) 2013-12-02 2018-06-27 Cerbios-Pharma S.A. Stable complexes of an alkaline earth metal salt of N5-methyl-tetrahydrofolic acid and a polyol
CN104490887A (zh) * 2014-09-04 2015-04-08 连云港金康和信药业有限公司 (6s)-5-甲基-四氢叶酸钙盐的稳定药物组合物
HUE054589T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Szájban diszpergálódó esztetrol tartalmú tabletta
MY195019A (en) 2015-06-18 2023-01-03 Estetra Sprl Orodispersible dosage unit containing an estetrol component
JP6866560B2 (ja) 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
MD3310346T2 (ro) 2015-06-18 2021-06-30 Estetra Sprl Comprimată orodispersabilă ce conține estetrol
CN105030779A (zh) * 2015-07-21 2015-11-11 福格森（武汉）生物科技股份有限公司 一种(6s)-5-甲基四氢叶酸钙口服营养补充剂及其制备方法
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
CN106336444A (zh) * 2016-08-23 2017-01-18 国家卫生计生委科学技术研究所 一种新晶型炔雌醇
CN107446458A (zh) * 2017-08-04 2017-12-08 合众（佛山）化工有限公司 一种高耐水性的丙烯酸改性聚氨酯杂化树脂水性涂料
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
CN110237046B (zh) * 2019-03-29 2021-07-30 福格森（武汉）生物科技股份有限公司 一种l-5-甲基四氢叶酸微囊的制备方法
CN110548034A (zh) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 一种怀孕阻断药物
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
IT202100008834A1 (it) * 2021-04-08 2022-10-08 Ind Chimica Srl Processo per la preparazione di drospirenone come polvere fine tramite duplice cambio di forma cristallina
CN114569567B (zh) * 2021-12-20 2023-03-14 南通联亚药业股份有限公司 一种稳定的双醋炔诺酮炔雌醇复方片及其制备方法
CN115813937B (zh) * 2022-12-01 2025-04-11 南通联亚药业股份有限公司 一种稳定的包含屈螺酮和雌二醇的药物组合物及其制备方法
WO2025132557A1 (en) * 2023-12-20 2025-06-26 Lesaffre Et Compagnie Solid formulations of tetrahydrofolates
CN117771389A (zh) * 2023-12-28 2024-03-29 浙江圣达生物药业股份有限公司 L-5-甲基四氢叶酸钙-γ-环糊精包合物及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3347125A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
FR2676927B1 (fr) * 1991-05-29 1995-06-23 Ibf Microspheres utilisables pour les occlusions vasculaires therapeutiques et solutions injectables les contenant.
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
DE4426709A1 (de) 1994-07-20 1996-01-25 Schering Ag Steroidale Sexualhormone enthaltende feste Arzneiformen
NZ293606A (en) 1994-09-22 1998-06-26 Akzo Nobel Nv Preparation of pharmaceutical dosage units of a steroidal progestogen by mixing with water and granulating the solution
RU2073529C1 (ru) * 1995-05-16 1997-02-20 Центральный научно-исследовательский рентгенорадиологический институт Композиция для эмболизации кровеносных сосудов
CH693255A5 (de) 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
CN1240387C (zh) * 1998-04-17 2006-02-08 奥索一麦克尼尔药品公司 含有叶酸的药用组合物及其用途和给药系统
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
HRP20020258B1 (hr) * 1999-08-31 2007-05-31 Schering Aktiengesellschaft Farmaceutska kombinacija etinilestradiola i drospirenona za upotrebu kao kontracepcijskog sredstva
ES2319750T3 (es) * 1999-08-31 2009-05-12 Bayer Schering Pharma Aktiengesellschaft Composicion farmaceutica que comprende etinilestradiol y drospirenona para usar como anticonceptivo.
EE05533B1 (et) 2000-01-18 2012-04-16 Schering Aktiengesellschaft Farmatseutiline kompositsioon ja preparaat, mis sisaldab mikroniseeritud drospirenooni ja ”strogeeni ning nende kasutamine
US6550482B1 (en) * 2000-04-21 2003-04-22 Vascular Control Systems, Inc. Methods for non-permanent occlusion of a uterine artery
US6864774B2 (en) 2000-10-19 2005-03-08 Matsushita Electric Industrial Co., Ltd. Inductance component and method of manufacturing the same
EP1216712A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
US6537569B2 (en) * 2001-02-14 2003-03-25 Microvention, Inc. Radiation cross-linked hydrogels
CA2476940C (en) * 2002-02-21 2011-11-01 Herman Jan Tijmen Coelingh Bennink Pharmaceutical compositions comprising one or more steroids, one or more tetrahydrofolate components and vitamin b12
WO2004039425A1 (ja) * 2002-10-29 2004-05-13 Toray Industries, Inc. 血管塞栓材料
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
CA2665788A1 (en) * 2006-07-06 2008-01-10 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical preparations for contraception and for preventing the risk of congenital malformations
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
RU61120U1 (ru) * 2006-10-13 2007-02-27 Закрытое акционерное общество "ААА-КОМПАНИ" Средство для эмболизации сосудов
RU62008U1 (ru) * 2006-10-13 2007-03-27 Закрытое акционерное общество "ААА-КОМПАНИ" Средство для эмболизации сосудов
US8916188B2 (en) * 2008-04-18 2014-12-23 Abbott Cardiovascular Systems Inc. Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block

Also Published As

Publication number Publication date
BRPI0713565A2 (pt) 2012-03-20
MX2009000079A (es) 2009-01-23
UA100228C2 (uk) 2012-12-10
CO6150125A2 (es) 2010-04-20
MY169516A (en) 2019-04-22
TNSN08543A1 (en) 2010-04-14
ES2626838T3 (es) 2017-07-26
AU2007271449A1 (en) 2008-01-10
HK1131917A1 (en) 2010-02-12
PH12012501774B1 (en) 2015-09-21
RU2479306C2 (ru) 2013-04-20
BRPI0713565B8 (pt) 2021-05-25
AU2007271449B2 (en) 2013-07-11
RU2624236C2 (ru) 2017-07-03
NO20090578L (no) 2009-03-09
ECSP099030A (es) 2009-02-27
IL196027A0 (en) 2009-09-01
CA2656131C (en) 2015-10-13
CR10549A (es) 2009-01-27
TW200812593A (en) 2008-03-16
MA30598B1 (fr) 2009-07-01
IL245355B (en) 2019-05-30
CA2856344C (en) 2017-02-28
KR20130042638A (ko) 2013-04-26
CN102813663B (zh) 2019-03-22
CN101484143B (zh) 2012-07-04
ES2626838T5 (es) 2024-03-14
IL245355A0 (en) 2016-06-30
EP2422774A1 (en) 2012-02-29
EP2422774B1 (en) 2015-08-12
RU2009103649A (ru) 2010-08-20
EP2040683B1 (en) 2017-03-01
CL2007001962A1 (es) 2008-01-04
CN101489563A (zh) 2009-07-22
UA105078C2 (uk) 2014-04-10
TW201538161A (zh) 2015-10-16
CA2656131A1 (en) 2008-01-10
EP2040683A1 (en) 2009-04-01
CA2856344A1 (en) 2008-01-10
AR061958A1 (es) 2008-08-10
ZA201501673B (en) 2016-02-24
AR106561A2 (es) 2018-01-24
CN102813663A (zh) 2012-12-12
GT200900001A (es) 2009-12-08
NZ573766A (en) 2011-05-27
ZA200900868B (en) 2021-05-26
NO347567B1 (no) 2024-01-15
ZA201808083B (en) 2021-06-30
NO20090578A (no) 2009-03-09
SG188869A1 (en) 2013-04-30
BRPI0713565B1 (pt) 2021-02-02
CU20090004A7 (es) 2011-07-11
ZA201808084B (en) 2021-06-30
WO2008003432A1 (en) 2008-01-10
JP2009542591A (ja) 2009-12-03
EP2040683B2 (en) 2023-08-16
RU2012133154A (ru) 2014-02-10
CU23902B1 (enExample) 2013-06-28
PE20080273A1 (es) 2008-05-16
PE20120375A1 (es) 2012-05-23
KR20090033889A (ko) 2009-04-06
PE20150287A1 (es) 2015-03-15
TWI508730B (zh) 2015-11-21
IL224484A (en) 2016-05-31
CN101484143A (zh) 2009-07-15
UY30462A1 (es) 2008-02-29

Similar Documents

Publication Publication Date Title
PH12012501774A1 (en) Pharmaceutical composition containing a tetrahydrofolic acid
WO2007048219A3 (en) Sustained drug release composition
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
MY157790A (en) Trazodone composition for once a day administration
EP3492069A3 (en) Pharmaceutical compositions
WO2006135638A3 (en) Tanaproget compositions containing ethinyl estradiol
UA100393C2 (ru) Новые офтальмологические композиции
PE20070208A1 (es) Anticoncepcion oral con trimegestona
EA201291372A1 (ru) Фармацевтическая композиция, содержащая дроспиренон, и набор для предупреждения зачатия
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
TW200501965A (en) Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle
IL164440A0 (en) New pharmaceutical composition containing fibanserin polymorph a
MX2009003169A (es) Derivados de sulfonamida.
TW200738283A (en) Formulations of conjugated estrogens and bazedoxifene
WO2007110765A3 (en) Processes for the preparation of octreotide
WO2008110337A3 (en) Pharmaceutical composition of quetiapine fumarate
TW200727892A (en) Formulations of suberoylanilide hydroxamic acid and methods for producing same
WO2002011740A3 (en) 'slow release' pharmaceutical compositions comprising lithium carbonate
MX2009001572A (es) Derivados de arilpiperazina y usos de los mismos.
TH98589A (th) องค์ประกอบทางเภสัชกรรมที่มีเททระไฮโดรโฟลิคแอซิด
TH98589B (th) องค์ประกอบทางเภสัชกรรมที่มีเททระไฮโดรโฟลิคแอซิด
WO2001095890A3 (en) Oral pharmaceutical compositions containing terbinafine
JOP20100287B1 (ar) مركب دوائي يشتمل على بروجستينات واستروجينات، احدهما او كلاهما، و5 - مثيل - (6s)- رابع هايدروفولات
DOP2007000117A (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas